David Weinberg
Chief Executive Officer Parcelbio
David Weinberg is the co-founder and CEO of ParcelBio. He was previously VP of RNA Platform at Orbital Therapeutics / Circ Bio, where he led the development of a circular RNA therapeutics platform. Before that, he was Senior Director of Molecular Research at Freenome, where he built the multiomics diagnostics platform that enabled a blood test for the early detection of cancer. David obtained his PhD from MIT, was a UCSF Faculty Fellow, and has been honored with Forbes ‘30 Under 30’ and an NIH Early Independence Award.
Seminars
Tuesday 21st July 2026
APEXm™ (Amplified & Prolonged EXpression mRNA) is a Modular Linear mRNA Platform for Potent & Durable Therapeutic Protein Expression
12:30 pm
- APEXm™ (Amplified and Prolonged EXpression mRNA) is a modular mRNA technology that confers potent and durable therapeutic protein expression from linear mRNA
- APEXm™ can be used to engineer mRNA for in vivo CAR-T applications, resulting in deep B-cell depletion from peripheral blood and lymphoid tissues in humanized mice and non-human primates
- APEXm™ enhances protein expression from any therapeutic mRNA across diverse cellular contexts and payloads, while maintaining simple manufacturing and compatibility with modified nucleotides
